RT Journal Article
T1 Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation.
A1 Cunha, Renato
A1 Zago, Marco A
A1 Querol, Sergio
A1 Volt, Fernanda
A1 Ruggeri, Annalisa
A1 Sanz, Guillermo
A1 Pouthier, Fabienne
A1 Kogler, Gesine
A1 Vicario, José L
A1 Bergamaschi, Paola
A1 Saccardi, Riccardo
A1 Lamas, Carmen H
A1 Díaz-de-Heredia, Cristina
A1 Michel, Gerard
A1 Bittencourt, Henrique
A1 Tavella, Marli
A1 Panepucci, Rodrigo A
A1 Fernandes, Francisco
A1 Pavan, Julia
A1 Gluckman, Eliane
A1 Rocha, Vanderson
A1 Eurocord, Cord Blood Committee Cellular Therapy–Immunobiology Working Party of the European Society for Blood and Marrow Transplantation, Netcord and Faculdade de Medicina de Ribeirão Preto–Faculdade de Medicina de São Paulo, Universidade de São Paulo
AB We evaluated the impact of recipient and cord blood unit (CBU) genetic polymorphisms related to immune response on outcomes after unrelated cord blood transplantations (CBTs). Pretransplant DNA samples from 696 CBUs with malignant diseases were genotyped for NLRP1, NLRP2, NLRP3, TIRAP/Mal, IL10, REL, TNFRSF1B, and CTLA4. HLA compatibility was 6 of 6 in 10%, 5 of 6 in 39%, and ≥4 of 6 in 51% of transplants. Myeloablative conditioning was used in 80%, and in vivo T-cell depletion in 81%, of cases. The median number of total nucleated cells infused was 3.4 × 107/kg. In multivariable analysis, patients receiving CBUs with GG-CTLA4 genotype had poorer neutrophil recovery (hazard ratio [HR], 1.33; P = .02), increased nonrelapse mortality (NRM) (HR, 1.50; P
YR 2016
FD 2016-11-03
LK http://hdl.handle.net/10668/10578
UL http://hdl.handle.net/10668/10578
LA en
DS RISalud
RD Apr 5, 2025